PDF(Pubmed)
Abstract：
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a significant threat to human health globally. It is crucial to develop a vaccine to reduce the effect of the virus on public health, economy, and society and regulate the transmission of SARS-CoV-2. Influenza B virus (IBV) can be used as a vector that does not rely on the current circulating influenza A strains. In this study, we constructed an IBV-based vector vaccine by inserting a receptor-binding domain (RBD) into a non-structural protein 1 (NS1)-truncated gene (rIBV-NS110-RBD). Subsequently, we assessed its safety, immunogenicity, and protective efficacy against SARS-CoV-2 in mice, and observed that it was safe in a mouse model. Intranasal administration of a recombinant rIBV-NS110-RBD vaccine induced high levels of SARS-CoV-2-specific IgA and IgG antibodies and T cell-mediated immunity in mice. Administering two doses of the intranasal rIBV-NS110-RBD vaccine significantly reduced the viral load and lung damage in mice. This novel IBV-based vaccine offers a novel approach for controlling the SARS-CoV-2 pandemic.
摘要：
严重急性呼吸道综合征冠状病毒2（SARS-CoV-2）对全球人类健康构成重大威胁。开发疫苗以减少病毒对公众健康的影响至关重要,经济,和社会，规范SARS-CoV-2的传播。B型流感病毒(IBV)可用作不依赖于当前循环的A型流感病毒株的载体。在这项研究中,我们通过将受体结合域（RBD）插入非结构蛋白1（NS1）截短的基因（rIBV-NS110-RBD），构建了基于IBV的载体疫苗。随后，我们评估了它的安全性,免疫原性,和对小鼠SARS-CoV-2的保护功效，并观察到它在小鼠模型中是安全的。鼻内施用重组rIBV-NS110-RBD疫苗在小鼠中诱导高水平的SARS-CoV-2特异性IgA和IgG抗体以及T细胞介导的免疫。施用两种剂量的鼻内rIBV-NS110-RBD疫苗显著降低了小鼠的病毒载量和肺损伤。这种基于IBV的新型疫苗提供了一种控制SARS-CoV-2大流行的新方法。
